Hybrid Closed-Loop with Faster Insulin Aspart Compared with Standard Insulin Aspart in Very Young Children with Type 1 Diabetes: A Double-Blind, Multicenter, Randomized, Crossover Study

What Was Tested

This randomized controlled trial paper looks at Insulin Aspart.

The researchers evaluated the use of hybrid closed-loop (HCL) insulin delivery with faster insulin aspart (Fiasp) in very young children with type 1 diabetes (T1D).

In a double-blind, multicenter, randomized, crossover study, children aged 2-6 years with T1D underwent two 8-week periods of HCL using CamAPS FX with Fiasp and standard insulin aspart (IAsp), in random order.

Who Took Part

According to the abstract, 25 participants were involved.

The age groups tagged for this paper are young children and children.

How the Study Was Run

In design terms this was a randomized, double-blind, crossover and multicenter study.

Random assignment meant chance, not the researchers, decided who got Insulin Aspart and who got the comparison, which limits bias.

Blinding on both sides kept the participants and researchers unaware of who received Insulin Aspart.

In the crossover set-up each of the participants took both Insulin Aspart and the comparison in turn, acting as their own control.

Running at several centres spread the Insulin Aspart study over different clinics and patient groups.

What Was Measured

The researchers evaluated the use of hybrid closed-loop (HCL) insulin delivery with faster insulin aspart (Fiasp) in very young children with type 1 diabetes (T1D).

Topics PubMed links to this paper include Diabetes Mellitus, Type 1, Insulin Aspart, Hypoglycemic Agents, Blood Glucose and Insulin.

Author keywords: Artificial pancreas, Closed-loop insulin delivery, Faster insulin aspart, Toddlers, Type 1 diabetes and Very young children.

What This Means in Plain Language

The paper is a randomized, double-blind and crossover study of Insulin Aspart in 25 participants.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2023 (Diabetes technology & therapeutics), a journal based in United States.

More context: the Insulin Aspart compound page, all human trials.